ATL-101 / Atalanta Therapeutics - LARVOL DELTA

Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical Trials (Businesswire) - "Atalanta Therapeutics...announced the completion of a $97 million Series B financing to support Phase 1 clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease. The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, funds managed by abrdn Inc, Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group, and GHR Foundation alongside existing investor F-Prime Capital....ATL-201 is Atalanta’s investigational therapy for KCNT1-related epilepsy, an early-onset seizure disorder and encephalopathy driven by gain-of-function variants in the KCNT1 gene....The company’s second development candidate, ATL-101, is a di-siRNA designed to silence the HTT gene for the treatment of Huntington’s disease....IND submissions planned in 2025 for first two programs within leading portfolio of di-siRNA therapies."

Financing • IND • Epilepsy • Huntington's Disease